Goldman Sachs
DMAC icon

Goldman Sachs’s DiaMedica Therapeutics DMAC Stock Holding History

Goldman Sachs’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Buy
168,066
+108,778
+183% +$668K ﹤0.01% 5083
2026
Q1 		$401K Sell
59,288
-70,100
-54% -$555K ﹤0.01% 5738
2025
Q4 		$1.03M Buy
129,388
+52,096
+67% +$390K ﹤0.01% 5117
2025
Q3 		$531K Buy
77,292
+59,388
+332% +$322K ﹤0.01% 5475
2025
Q2 		$69.8K Sell
17,904
-103,898
-85% -$405K ﹤0.01% 5878
2025
Q1 		$462K Buy
121,802
+52,854
+77% +$302K ﹤0.01% 5235
2024
Q4 		$374K Buy
+68,948
New +$325K ﹤0.01% 5396
2019
Q3 		– Sell
-51,061
Closed -$253K – 5208
2019
Q2 		$253K Buy
+51,061
New +$177K ﹤0.01% 4686

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs's DMAC Position: Q2 2026 in Review

Goldman Sachs increased its DiaMedica Therapeutics (DMAC) stake by 183% in Q2 2026, buying an estimated $668K and bringing the position to 168,066 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #5083.

Goldman Sachs first reported a position in DMAC in Q2 2019 and has held it in 8 quarters since. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Goldman Sachs held 168,066 shares of DiaMedica Therapeutics worth $1.18M as of Q2 2026.
  • Goldman Sachs bought 108,778 DiaMedica Therapeutics shares in Q2 2026, an estimated $668K.
  • DiaMedica Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5083 holding.
  • Goldman Sachs first reported a position in DiaMedica Therapeutics in Q2 2019 and has held it in 8 quarters since.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.